검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Inhaled Long-Acting Beta Agonist (Inhaled Long-Acting Beta Agonist) Sanofi·Chronic Obstructive Pulmonary Dise… ORR 7.6% |
|---|---|
Overview Program | Inhaled Long-Acting Beta Agonist |
Overview Company | Sanofi |
Overview Modality | ANTIBODY |
Overview Target | Chronic Obstructive Pulmonary Disease |
Overview Indication | Chronic Obstructive Pulmonary Disease |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
MoA Mechanism | of LAMA is bronchodilation through antagonism of M 3 muscarinic acetylcholine (ACh) receptors (mAChR) on airway smooth muscle |
MoA Biomarker | biomarkers are established therapeutic targets in asthma and non-asthmatic eosinophilic bronchitis (NAEB), bu |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vilanterol, a Novel Inhaled Long-Acting β-Agonist, in Children Aged 5-11 Years with Persistent Asthma: A Randomized Trial.. This multi-center, randomized, double-blind, placebo-controlled, two-way crossover study was designed to characterize the safety, tolerability, pharmacokinetic, and pharmacodynamic profile of single and onc… |
Clinical Primary efficacy | ORR 7.6% |
Clinical ORR | 7.6% |
Clinical Result source | ClinicalTrials.gov NCT03250689 |
Clinical Data Tier / Score | A · 40 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Inhaled Long-Acting Beta Agonist (Inhaled Long-Acting Beta Agonist) Sanofi·Chronic Obstructive Pulmonary Dise… ORR 7.6% |
|---|---|
Overview Program | Inhaled Long-Acting Beta Agonist |
Overview Company | Sanofi |
Overview Modality | ANTIBODY |
Overview Target | Chronic Obstructive Pulmonary Disease |
Overview Indication | Chronic Obstructive Pulmonary Disease |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
MoA Mechanism | of LAMA is bronchodilation through antagonism of M 3 muscarinic acetylcholine (ACh) receptors (mAChR) on airway smooth muscle |
MoA Biomarker | biomarkers are established therapeutic targets in asthma and non-asthmatic eosinophilic bronchitis (NAEB), bu |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vilanterol, a Novel Inhaled Long-Acting β-Agonist, in Children Aged 5-11 Years with Persistent Asthma: A Randomized Trial.. This multi-center, randomized, double-blind, placebo-controlled, two-way crossover study was designed to characterize the safety, tolerability, pharmacokinetic, and pharmacodynamic profile of single and onc… |
Clinical Primary efficacy | ORR 7.6% |
Clinical ORR | 7.6% |
Clinical Result source | ClinicalTrials.gov NCT03250689 |
Clinical Data Tier / Score | A · 40 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교